Simplex Trading’s Summit Therapeutics SMMT Stock Holding History

Simplex Trading’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$159K	Buy	+8,410	New	+$136K	﹤0.01%	4572
2024 Q3	–	Sell	-114,647	Closed	-$1.6M	–	9499
2024 Q2	$894K	Buy	+114,647	New	+$619K	﹤0.01%	3035
2023 Q3	–	Sell	-25,114	Closed	-$47.9K	–	9732
2023 Q2	$63K	Buy	25,114 +12,678	+102%	+$23.1K	﹤0.01%	5599
2023 Q1	$21K	Sell	12,436 -3,093	-20%	-$8.44K	﹤0.01%	6876
2022 Q4	$65K	Buy	+15,529	New	+$28.2K	﹤0.01%	5557
2022 Q3	–	Sell	-63	Closed	-$71	–	10804
2022 Q2	$0	Buy	+63	New	+$88	﹤0.01%	11001
2022 Q1	–	Sell	-1,578	Closed	-$3.98K	–	11322
2021 Q4	$4K	Sell	1,578 -607	-28%	-$2.92K	﹤0.01%	9709
2021 Q3	$17K	Sell	2,185 -731	-25%	-$5.25K	﹤0.01%	8574
2021 Q2	$21K	Buy	+2,916	New	+$19.1K	﹤0.01%	8558
2018 Q4	–	Sell	-23,282	Closed	-$51K	–	7747
2018 Q3	$51K	Buy	23,282 +15,663	+206%	+$36.1K	﹤0.01%	5149
2018 Q2	$18K	Buy	+7,619	New	+$97.6K	﹤0.01%	5951

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Simplex Trading's SMMT Position: Q1 2026 in Review

Simplex Trading opened a new position in Summit Therapeutics (SMMT) in Q1 2026: 8,410 shares worth $159K. The stake represents ﹤0.01% of the portfolio and ranks #4572 among its holdings. This is a return to the name: Simplex Trading previously reported a position in SMMT as recently as Q2 2024.

Simplex Trading first reported a position in SMMT in Q2 2018 and has held it in 11 quarters since. The position peaked at $894K in Q2 2024. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

Simplex Trading held 8,410 shares of Summit Therapeutics worth $159K as of Q1 2026.
Summit Therapeutics was a new Simplex Trading position in Q1 2026.
Summit Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #4572 holding.
Simplex Trading first reported a position in Summit Therapeutics in Q2 2018 and has held it in 11 quarters since.
Simplex Trading's Summit Therapeutics position peaked at $894K in Q2 2024.
222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.